TANDEM study shows potential of HistoIndex SHG/TPE imaging and AI-based technology in evaluating the effects of combination therapy for NASH   SINGAPORE, June 15, 2023 – Recent findings from the TANDEM study (NCT03517540) in 193 patients with nonalcoholic steatohepatitis (NASH) reveal the use of HistoIndex’s Second Harmonic Generation/Two-Photon Excitation (SHG/TPE) imaging and Artificial Intelligence (AI) […]

HistoIndex SHG/TPE imaging and AI-based technology reveals dose-dependent effectiveness of Tropifexor for NASH patients in Nature Medicine   SINGAPORE, June 15, 2023 – HistoIndex has announced that its novel technology combining Second Harmonic Generation/Two-Photon Excitation (SHG/TPE) imaging with Artificial Intelligence (AI), in a post hoc analysis of the FLIGHT-FXR study (NCT02855164), enabled the detection of

HistoIndex embarks on partnership with VCU’s Stravitz-Sanyal Institute for Liver Disease and Metabolic Health in the study of liver diseases   Advancing ML/AI-based technology in the study of liver diseases by furthering strategic partnerships using a stain-free digital pathology system. SINGAPORE, April 10, 2023 – Virginia Commonwealth University’s Stravitz-Sanyal Institute for Liver Disease and Metabolic

Appointment of Dr. David John Jeans CBE as HistoIndex’s Non-Executive Chairman   SINGAPORE, Jan. 9, 2023 – The Board of Directors (the “Board”) of HistoIndex (the “Company”) would like to announce the following changes in appointments to the Board with effect from 6th December 2022: (1) Mr Sim Giok Lak’s decision to step down as Non-Executive Chairman of the

HistoIndex Stain-free AI-DP Reveals Treatment-induced Zonal Regression of Fibrosis Colocalized with Reduction in Steatosis & Hepatocyte Ballooning in FLIGHT-FXR NASH Clinical Trial   SINGAPORE, July 29, 2022 – HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, announced that its AI-based qFibrosis®, qSteatosis® and qBallooning® algorithms delivered sensitivity and granularity on a greater scale, as compared with

HistoIndex and Global Liver Experts Advance Stain-free AI Quantification of Hepatocyte Ballooning as a Reproducible Approach and Potential Endpoint for NASH Clinical Trials This is a first-of-its-kind international study initiated in 2019 by HistoIndex to examine artificial intelligence (AI)-based approaches that may provide a more reliable way to assess the range of injury recorded as “hepatocyte

HistoIndex and Galecto to Collaborate on Galecto’s Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis Assessment with AI-based Stain-free Digital Pathology   SINGAPORE, Oct. 20, 2021 – HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, has announced a collaboration with Galecto, Inc., a biotechnology company focused on the development of novel treatments for fibrosis and cancer.

HistoIndex’s Stain-free AI-based Digital Pathology Incorporated as Secondary and Exploratory Efficacy Endpoints in Sagimet’s NASH FASCINATE-2 Phase 2b Clinical Trial   Singapore, 18 August, 2021 – HistoIndex, a global leading artificial intelligence (AI) digital pathology provider, has announced an agreement with clinical-stage biotechnology company Sagimet Biosciences. HistoIndex’s integrated suite of stain-free imaging with AI-based fully quantitative and

HistoIndex’s AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in Nonalcoholic Steatohepatitis (NASH) Patients Treated with Tropifexor Compared with Placebo   SINGAPORE, June 25, 2021 – HistoIndex’s Second Harmonic Generation (SHG) stain-free digital pathology platform has shown marked reduction in liver fibrosis (overall, reduction in perisinusoidal fibrosis, as well as regression of

HistoIndex Explores the Clinical Utility of Stain-free AI Digital Pathology Platform in 388 Patients with Triple-Negative Breast Cancer (TNBC)   Assessing the morphological and architectural changes in collagen fibers with the platform could potentially aid TNBC clinical trials in categorizing patients and monitoring therapeutic responses.   SINGAPORE, Jan. 24, 2021 – HistoIndex’s stain-free AI digital